124 related articles for article (PubMed ID: 2501865)
1. Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrate.
Spencer AJ; Barbolt TA; Henry DC; Eason CT; Sauerschell RJ; Bonner FW
Toxicol Pathol; 1989; 17(1 Pt 1):7-15. PubMed ID: 2501865
[TBL] [Abstract][Full Text] [Related]
2. Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmoset.
Eason CT; Spencer AJ; Pattison A; Howells DD; Henry DC; Bonner FW
Toxicol Appl Pharmacol; 1988 Sep; 95(2):328-38. PubMed ID: 3138789
[TBL] [Abstract][Full Text] [Related]
3. Assessment of gastric antisecretory effects of phenoxyisobutyrate derivatives in the rat and the mouse.
Eason CT; Pattison A; Howells DD; Spencer AJ; Bonner FW
Scand J Gastroenterol; 1988 Nov; 23(9):1063-71. PubMed ID: 3247588
[TBL] [Abstract][Full Text] [Related]
4. The effect of ciprofibrate on gastric secretion in the rat.
Eason CT; Pattison A; Howells DD; Bonner FW
J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
[TBL] [Abstract][Full Text] [Related]
5. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole.
Betton GR; Dormer CS; Wells T; Pert P; Price CA; Buckley P
Toxicol Pathol; 1988; 16(2):288-98. PubMed ID: 2903544
[TBL] [Abstract][Full Text] [Related]
6. Antral G cells in rats during dosing with a PPAR alpha agonist: a morphometric and immunocytochemical study.
Martinsen TC; Skogaker NE; Bendheim MØ; Waldum HL
Med Electron Microsc; 2003 Mar; 36(1):18-32. PubMed ID: 12658348
[TBL] [Abstract][Full Text] [Related]
7. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
Rao MS; Dwivedi RS; Subbarao V; Reddy JK
Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
[TBL] [Abstract][Full Text] [Related]
8. Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset.
Makowska JM; Bonner FW; Gibson GG
Arch Toxicol; 1991; 65(2):106-13. PubMed ID: 1905530
[TBL] [Abstract][Full Text] [Related]
9. Gastric enterochromaffin-like cell hyperplasia and neoplasia in the rat: an indirect effect of the histamine H2-receptor antagonist, BL-6341.
Hirth RS; Evans LD; Buroker RA; Oleson FB
Toxicol Pathol; 1988; 16(2):273-87. PubMed ID: 2903543
[TBL] [Abstract][Full Text] [Related]
10. The peroxisome-proliferator ciprofibrate induces hypergastrinemia without raising gastric pH.
Martinsen TC; Nesjan N; Rønning K; Sandvik AK; Waldum HL
Carcinogenesis; 1996 Oct; 17(10):2153-5. PubMed ID: 8895482
[TBL] [Abstract][Full Text] [Related]
11. The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particularly the gastrin cell.
Waldum HL; Kvetnoi IM; Sylte R; Schulze B; Martinsen TC; Sandvik AK
J Mol Endocrinol; 1998 Feb; 20(1):111-7. PubMed ID: 9513087
[TBL] [Abstract][Full Text] [Related]
12. Potentiating hypergastrinemic effect by the peroxisome proliferator ciprofibrate and omeprazole in the rat.
Hammer TA; Sandvik AK; Waldum HL
Scand J Gastroenterol; 1998 Jun; 33(6):595-9. PubMed ID: 9669630
[TBL] [Abstract][Full Text] [Related]
13. Incidence of pancreatic and testicular tumors in rats treated with ciprofibrate, a peroxisome proliferator.
Rao MS; Subbarao V
Cancer Lett; 1995 Nov; 97(2):185-8. PubMed ID: 7497461
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
Arnold A; McAuliff MP; Beyler AL
J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
[TBL] [Abstract][Full Text] [Related]
15. Ciprofibrate--racemate and enantiomers: effects of a four-week treatment on male inbred Fischer rats. A biochemical and morphological study.
Klinger W; Lupp A; Karge E; Oelschläger H; Rothley D; Danz M; Linss W; Löbel S; Deufel T; Müller M; Klinger M; Kühnel W
Exp Toxicol Pathol; 1998 Sep; 50(4-6):301-14. PubMed ID: 9784002
[TBL] [Abstract][Full Text] [Related]
16. The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat.
Eason CT; Powles P; Henry G; Spencer AJ; Pattison A; Bonner FW
Xenobiotica; 1989 Aug; 19(8):913-25. PubMed ID: 2815833
[TBL] [Abstract][Full Text] [Related]
17. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
[TBL] [Abstract][Full Text] [Related]
18. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
[TBL] [Abstract][Full Text] [Related]
19. Species differences in the hepatic response to a potent peroxisome proliferator.
Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
[No Abstract] [Full Text] [Related]
20. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
Oelschläger H; Rothley D; Hellwich KH; Schmidt W
Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
